MPM BioVentures 2014, L.P. sold $201k of HOWL
owner at Werewolf Therapeutics, Inc.. 209,652 shares at an average of $0.96, traded Nov 13, 2025, filed Nov 17, 2025.
Score components
- +12Role10% owner
- +12Trade size$201k at market
- 0Share of holdings soldSold 3.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000509, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -90,951 | $0.98 | $89k | 5,600,240 | Nov 17, 2025 |
| Nov 14, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -61,640 | $0.93 | $57k | 5,538,600 | Nov 17, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See Footnotes10b5-1 | -57,061 | $0.95 | $54k | 5,481,539 | Nov 17, 2025 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $21k 38,782 shares | -2% | |
| 2Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $62k 111,227 shares | -5% | |
| 2Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $54k 91,374 shares | -4% | |
| 1Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $46k 71,054 shares | -3% | |
| 2Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $48k 78,377 shares | -3% | |
| 12Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $185k 291,283 shares | -10% | |
| 17Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $52k 48,171 shares | -2% | |
| 19Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $89k 82,971 shares | -3% | |
| 20Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $95k 95,179 shares | -3% | |
| 20Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $118k 128,185 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.